The resolution of airway inflammation in asthma and chronic obstructive pulmonary disease

Walsh, Garry Michael; McDougall, Catherine

doi:10.1007/978-3-7643-7506-5_9

Cited by 6 publications

(3 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-13 is thought to be a key mediator of asthma; for example it was significantly elevated in BAL following allergen provocation of asthmatic subjects, which strongly correlated with the increase in eosinophil numbers while mRNA expression for IL-13 was detected in bronchial biopsies from both allergic and non-allergic asthmatic subjects. In animal models, IL-13 mimics many of the pro-inflammatory changes associated with asthma [58,59]. It is therefore another potential therapeutic target for the resolution of airway inflammation.…”

Section: Interleukin-13mentioning

confidence: 99%

“…The latter exists in soluble form and has a high affinity for IL-13 and can thus "mop up" secreted IL-13; in mice IL-13R 2 blocked the actions of IL-13, including IgE production, pulmonary eosinophilia and AHR [60]. A humanised IL-13R 2 is now in clinical development as a novel therapy for asthma [59]. Another mousebased study reported that intratracheal administration of human IL-13 induced leukocyte infiltration in the lung, AHR, and goblet cell metaplasia with allergic eosinophilic inflammation in the oesophagus.…”

Section: Interleukin-13mentioning

confidence: 99%

“…Humanised mAb effective in mouse asthma models [60,61] reduced BAL eosinophils, eotaxin and RANTES in cynomolgus monkeys sensitised to Ascaris suum [63]. Reduced LAR in sheep model of allergic asthma [64] Humanised IL-13R 2 in clinical development [59] Eotaxin SMA CCR3…”

Section: H1-receptor Antagonistmentioning

confidence: 99%

See 2 more Smart Citations

Recent Developments in Targeting Eosinophil Accumulation as a Novel Therapeutic Approach for Asthma

Walsh¹,

Robinson²,

Zhang³

2008

TOALLJ

Self Cite

View full text Add to dashboard Cite

Current therapies for asthma are aimed at controlling disease symptoms and for the majority of patients inhaled glucocorticoid anti-inflammatory therapy is both effective and well-tolerated. However, concerns remain about the adverse effects of glucocorticoids while a subset of asthmatic patients remains symptomatic despite optimal treatment thereby creating a clear unmet medical need. There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the μ1 and μ2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise the problems and successes regarding recent developments in therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.

show abstract

Section: Interleukin-13mentioning

confidence: 99%

Section: Interleukin-13mentioning

confidence: 99%

See 1 more Smart Citation

Recent Developments in Targeting Eosinophil Accumulation as a Novel Therapeutic Approach for Asthma

Walsh¹,

Robinson²,

Zhang³

2008

TOALLJ

Self Cite

View full text Add to dashboard Cite

show abstract

Allergy and Asthma: Small Molecule Approaches

Walsh

2008

Wiley Encyclopedia of Chemical Biology

View full text Add to dashboard Cite

Current therapies for asthma and allergy are aimed at controlling disease symptoms. For most asthmatics, inhaled anti‐inflammatory therapy is effective, but a subset of patients remains symptomatic despite optimal treatment creating a clear unmet medical need. Although considered a less‐serious condition than asthma, allergic diseases are common and considerably impact on the quality of life of affected individuals. Innovative disease‐modifying therapeutics are needed for both allergy and asthma. Biopharmaceutical approaches may identify small molecules that target key cells and mediators that drive the inflammatory responses that underlie the pathogenesis of allergy and asthma.

show abstract

Allergy and Asthma

Walsh

2012

Chemical Biology

View full text Add to dashboard Cite

The resolution of airway inflammation in asthma and chronic obstructive pulmonary disease

Cited by 6 publications

References 170 publications

Recent Developments in Targeting Eosinophil Accumulation as a Novel Therapeutic Approach for Asthma

Recent Developments in Targeting Eosinophil Accumulation as a Novel Therapeutic Approach for Asthma

Allergy and Asthma: Small Molecule Approaches

Allergy and Asthma

Contact Info

Product

Resources

About